Lilly, Nvidia to establish $1B AI co-innovation lab in San Francisco
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Health Care & Life Sciences
Articles
New Riley Children’s Foundation CEO looks to exceed $300M fundraising goal
Courtney Roberts’ job is to help ensure that when children with serious illnesses, injuries and conditions must be in the hospital, Riley Health is fully funded to meet their medical and care needs and to advance research to also improve care.
Lilly to acquire California-based biopharma company in $1.2B deal
Indianapolis-based Eli Lilly and Co. announced Wednesday it intends to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral therapies for inflammatory-mediated diseases.
Elanco reaches for growth in billion-dollar itchy dog market
The Indianapolis-based company received U.S. regulatory approval last week for its second medicine in 18 months in what it describes as the $1.3 billion dog dermatology market.
Indiana attorney general sues Lilly over insulin prices
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
Tariff worries spur growth of Indiana life sciences group purchasing program
Participants in the program via the Indiana Life Sciences Association can receive significant discounts—up to 75%—off list prices on goods including lab equipment, office supplies, corporate travel and insurance.
2025 Newsmaker: David Ricks
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Lilly’s growth explosion tests state’s workforce development
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
Lilly Phase 3 trial shows GLP-1 pill effective for weight-loss maintenance
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.
State health insurance plan changes reflect Braun’s vision
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that limits choice.
Elanco announces plans to bolster Indy-based R&D, cut 300 jobs worldwide
An Elanco spokeswoman said cuts to the company’s Indiana workforce are “very minimal.” Most of the eliminated positions are from the company’s planned closure of its German R&D facility.
Lilly to build $6B plant in Alabama in 3rd of 4 big US investments
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Lilly cuts prices on Zepbound vials sold on LillyDirect
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
Lilly rolling out direct-to-employer obesity drug coverage
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Jim Lefevere: Can state turn health innovation momentum into sustainable scale?
Yet promising health tech companies still leave the state to raise growth capital.
Roche survey: Many millennial women skipping cervical cancer screenings
Indianapolis-based Roche Diagnostics said while the survey was conducted in Europe, its implications are global and reflect challenges in the United States.
Orthopedic surgeon takes blunt approach to reforming care
Dr. Michael Meneghini waited out a two-year noncompete clause after leaving Indiana University Health before opening the $35 million Indiana Orthopedic Institute early this year.
New Indianapolis venture studio aims to launch 8-12 startups in next few years
Indianapolis-based Alloy Partners says its OneHealth Studio, a venture studio that quietly began operating last month in partnership with Elanco Animal Health Inc., will be ready to create its first startups early next year.
Elanco’s Q3 earnings top Wall Street forecasts as company continues to deal with debt
Despite reporting a loss, the company saw quarterly growth in the double digits and raised its full-year earnings estimate.